Cargando…
抗PD-1/PD-L1单抗治疗肺癌临床研究进展
Recently, the immune checkpoint inhibitors which target programmed death-1 (PD-1)/PD-1 ligand (PD-L1) have made a breakthrough in the treatment of advanced non-small cell lung cancer. Researches on immune checkpoint inhibitors have been rapidly implemented in various types of lung cancer, such as sm...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000315/ https://www.ncbi.nlm.nih.gov/pubmed/26582228 http://dx.doi.org/10.3779/j.issn.1009-3419.2015.11.09 |